Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Details for Australian Patent Application No. 2007260356 (hide)

Owner H. Lundbeck A/S

Inventors Stensbol, Tine Bryan; Faldt, Andre; Miller, Silke; Bang-Andersen, Benny; Lopez De Diego, Heidi

Agent Watermark

Pub. Number AU-A-2007260356

PCT Pub. Number WO2007/144006

Priority PA 2006 00816 16.06.06 DK; PA 2007 00423 20.03.07 DK; 60/805,009 16.06.06 US

Filing date 15 June 2007

Wipo publication date 21 December 2007

International Classifications

C07D 211/20 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

A61K 31/451 (2006.01) - having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine

A61P 25/04 (2006.01) Drugs for disorders of the nervous system

A61P 25/22 (2006.01) Drugs for disorders of the nervous system

A61P 25/24 (2006.01) Drugs for disorders of the nervous system

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

A61P 25/32 (2006.01) Drugs for disorders of the nervous system

A61P 25/34 (2006.01) Drugs for disorders of the nervous system

A61P 25/36 (2006.01) Drugs for disorders of the nervous system

Event Publications

15 January 2009 PCT application entered the National Phase

  PCT publication WO2007/144006 Priority application(s): WO2007/144006

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007260358-Switching circuit

2007260355-1- [2- (2, 4-dimethylphenylsulfanyl) - phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment